← Compounds
Fezolinetant (Veozah)
on-label Rx · comparatorFDA-approvedNK3R antagonism (thermoregulatory)
Overview
NK3R antagonist — the validated NON-hormonal therapy for menopausal vasomotor symptoms. Not a peptide; the comparator no peptide beats for hot flashes.
How it works
- Neurokinin-3 receptor antagonism in the thermoregulatory center
Dosing
45 mg once daily.
Oral45 mg standard· daily
Cycling
- Continuous
Side effects
- Common
- Headache
- Abdominal pain
- Warnings
- Hepatotoxicity — LFT monitoring
Verified citations
3 · PubMed-checked- Fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1).clinicalPMID 36924778 ↗
- Efficacy and Safety of Fezolinetant in Vasomotor Symptoms Associated With Menopause: Phase 3 RCT.clinicalPMID 36734148 ↗
- Fezolinetant in the treatment of vasomotor symptoms associated with menopause.reviewPMID 33724119 ↗
Reconstitution
Not applicable — this compound is oral. No vial reconstitution needed.
Used for
Legal / compounding
FDA-approved
- FDA
- Approved (Veozah)
Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.